Financials

Financials — What the Numbers Say

Convatec is a $2.4B-revenue chronic-care medical-products business with consistently improving gross margins (now ~56%), reported operating margins still depressed by acquisition-intangible amortization, and a free-cash-flow profile that finally re-accelerated to a 13.7% margin in 2025. The balance sheet sits at investment-grade BBB with net debt at 2.0x adjusted EBITDA, but cash has fallen to $68M after a $326M buyback in 2025. The market is pricing the stock as if the margin promise will not arrive: shares trade at 52-week lows (205.2p on 8 May 2026), down ~16% year-to-date and ~24% below the consensus 12-month target near 303p. The single financial metric that matters now is the gap between IFRS operating margin (13.0%) and management's adjusted operating margin (≥23% guided for 2026, 24-26% by 2027) — and how much of it is real cash.

1. Financials in One Page

The reader's investment chain. Revenue is growing again (5-7% organic guide). Gross margin is firm at 56%. The reported P&L looks weaker than peers because $200M+ of annual amortization sits in the income statement; the cash flow does not pay it. Free cash flow, dividends, and the buyback are real. Net debt is back near 2x but inside Fitch BBB. Returns on capital are improving but not yet peer-leading. Valuation has compressed to the cheapest end of the multi-year range, and the current price reflects an overhang from a private-equity-style placement, tariff worries, and Unomedical/InnovaMatrix regulatory noise — not a financial-quality break.

2. Revenue, Margins, and Earnings Power

Convatec went public in October 2016 at the tail end of a large debt-funded recapitalisation, so the early IFRS numbers are noisy. The clean read starts in 2017: revenue compounded ~4.7% over FY17-FY25 with a clear acceleration into 2024-25 driven by the FISBE strategy, new Wound Biologics and infusion-care launches, and US Home Services Group integration.

The shape tells the story. Revenue has grown every year since 2017 except for a flat 2019. Operating income, by contrast, jumped in 2017-18 (early post-IPO synergies), collapsed in 2019 on a $130M+ accounting and impairment hit, recovered slowly through 2020-22, then stepped up to $325M in 2024 before backing off to $316M in 2025 on tariff and restructuring drag. The trajectory is no longer flat — 2024-25 is the first time the IFRS operating profit number has cleared the FY18 high.

Gross margin is the most reliable signal. It has climbed from 51% to 56% over a decade — a structural, mix-driven gain from higher-margin Advanced Wound Care, Continence Care direct-to-consumer, and pricing actions. Operating margin is messier because it carries acquired-intangible amortization (~$160-200M a year) that the FISBE strategy did not create.

Why the FY25 step-down vs FY24. Reported operating profit fell from $325M to $316M despite revenue rising $150M. Management attributes this to incremental tariff costs (c.20bps headwind, all in H1 2026 per FY26 guidance), restructuring associated with the Accelerate strategy, and continued investment in US Home Services. The company simultaneously upgraded its medium-term targets — adjusted operating margin to 24-26% by 2027 (from previous mid-20s%) and organic revenue growth to 6-8% from 2027 — which is a confident signal at the wrong moment for IFRS.

H2 2025 is the period to interrogate. Revenue accelerated to $1,259M (+7.1% YoY) but the IFRS operating margin compressed to 10.9% from H1's 15.2%. That is the tariff and Unomedical FDA-related spending hitting at once, alongside the InnovaMatrix CMS competitive-bidding overhang. Management still guides to ≥23% adjusted operating margin in FY26, suggesting the H2 weakness is treated as transitory.

3. Cash Flow and Earnings Quality

The terms first. Operating cash flow (OCF) is the cash a business generates from its day-to-day operations after working-capital changes. Free cash flow (FCF) is OCF minus capital expenditures — the cash actually available for dividends, buybacks, debt repayment, or acquisitions. Cash conversion compares cash to accounting profit; if the two diverge, you must understand why.

Operating cash flow has consistently been two to four times reported net income since 2017. That gap is the earnings-quality signal — and it is real, not aggressive accounting. The bridge is mostly amortization of acquired intangibles ($200M+ a year) plus depreciation, both non-cash. So Convatec's audited net income systematically understates the cash this business produces. The $470M OCF in FY25 is the highest in company history.

The FCF margin trough in FY22 (6.6%) was not an accounting issue — it was three real things at once: working-capital build (DIO climbed from 121 to 142 days), step-up in growth capex (capex/revenue rose to 7.0%), and acquisition-related cash outflows. Through FY24-25 inventory days have come back down, working capital has stabilised, and FCF margin has rebuilt to 13.7%. Capex intensity at ~5.5% of revenue is normal for a med-tech manufacturer with global plants in Mexico, Slovakia, and the UK.

The notable FY25 movement is the $326M buyback — Convatec's first material repurchase in the company's history. Combined with $140M of dividends, total cash returned to shareholders was $466M, well above $335M of FCF and the gap was funded by new debt issuance (a $500M ten-year senior unsecured note). SBC at $28M is real but small at 1.1% of revenue. There are no obvious accounting red flags in the cash statement.

4. Balance Sheet and Financial Resilience

The balance sheet today is fundamentally different from the over-leveraged 2013-15 entity that was carrying $3.5B+ of net debt as a pre-IPO LBO. Net debt has fallen to $1,450M (2.6x trailing IFRS EBITDA, 2.0x adjusted EBITDA per company definitions), and Fitch reaffirmed BBB on 25 February 2026.

Two things are happening at once. Convatec has used FCF to deliver a steady, multi-year deleveraging from 4x to ~2x net debt / EBITDA. But in FY25, they reversed course modestly: $326M of buybacks drained equity from $1,689M to $1,518M, cash held at a lean $68M, and total debt rose by $300M after issuing a $500M 10-year unsecured note (used to refinance and fund returns). Net debt rose $313M to $1,450M. Management is leaning into a ~2.0x leverage corridor rather than continuing to deleverage — a deliberate capital-structure decision.

Quality signals to flag. Goodwill and intangibles together are $1,996M — 53% of total assets, 132% of equity. That is the legacy of the 2008 buyout structure and subsequent bolt-ons. There has been no recent impairment, but the headline tangible book value is negative: $1,518M equity minus $1,996M intangibles = -$478M tangible book. Current ratio of 1.53x is adequate. DSO at 56 days, DIO at 131 days, DPO at 150 days produces a 38-day cash conversion cycle that has improved from 49 days a year ago. The supplier financing (DPO > DIO + DSO) suggests the working-capital position is comfortable.

5. Returns, Reinvestment, and Capital Allocation

ROIC has roughly doubled from 5% in 2021 to 7.6-8.0% in 2024-25. That is real progress, but it is still below management's likely cost of capital (typically 8-10% for a med-tech) and meaningfully below pure-play peers like Coloplast (10%) or Insulet (34%). ROE at ~11% is within reach of the cost of equity but is partly engineered by leverage, not pure operating return. The capital allocation framework will need to keep delivering reinvestment-led margin expansion to lift IFRS ROIC into double digits.

The change of regime in FY25 is unmistakable: the first material buyback in company history ($326M, ~7% of opening market cap), funded with new long-dated debt rather than balance-sheet cash. Combined with rising dividends (full-year DPS of 7.244 cents, +13% YoY), total shareholder yield in FY25 was roughly 8% on the FY24 closing market cap — the highest in the company's listed history. M&A spend has come down sharply from the FY21-23 average of $148M to $24M as management prioritises organic execution.

For the first time in the company's listed life, the share count is falling — weighted average shares dipped from 2,048M in FY24 to 2,025M in FY25, and end-of-period shares dropped to 1,954M. FCF per share grew from 13.4 cents to 16.6 cents in 2025 (+24%), which outpaces revenue growth (+6.6%) — a textbook sign of management compounding per-share value rather than just growing the company.

6. Segment and Unit Economics

Convatec organises around four franchises — Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care — each with its own R&D, commercial, and supply chains. Detailed segment financials by franchise are not present in the data files used for this page. Press release and CMD commentary indicate Advanced Wound Care has been the largest growth contributor, with InnovaMatrix in Wound Biologics and ConvaFoam launches as key drivers, while Infusion Care is exposed to insulin-pump customer concentration (notably Insulet's Omnipod) and to the Unomedical Mexico-City FDA Remote Regulatory Assessment finding flagged in early 2026.

The geographic mix is roughly half North America, with the remainder split across Europe, the Middle East, Africa, Asia-Pacific, and Latin America. This matters for the FY26 tariff overhang: the c.20bps adjusted-operating-margin headwind from US tariffs lands disproportionately in H1 2026 because the company manufactures in Mexico and Slovakia and ships into the US. Management has called out tariffs as the largest controllable margin variable for the year.

7. Valuation and Market Expectations

The right valuation framework for Convatec is EV/EBITDA and P/FCF, because the IFRS P/E is distorted by acquired-intangible amortization and the cash story is what investors actually own. P/E is shown for completeness but should not anchor the verdict.

The FY25 EV/EBITDA of 14.5x is below the 7-year average (~15-16x) and the FY24 reading of 12.5x was the cheapest the stock has been since IPO. Note: the FY25 multiple is calculated against the 31 December 2025 share price (243p); the stock has since fallen another 16% to 205p, implying a current EV/EBITDA closer to 12-13x and a current P/FCF closer to 15-16x. FCF yield at the current price is ~6.2%, the most attractive level since 2018.

Reading: applying mid-range multiples to a base-case +10% FCF (~$370M) and current EBITDA of ~$540M (FY26 modestly higher on margin guide) frames a base-case scenario near 260p — close to the consensus average of 303p across 17 sell-side analysts (Berenberg 330p Buy, RBC 320p Sector Perform, JP Morgan/Goldman/UBS Buy). The bear scenario requires the adjusted-margin path to slip below 23% and sentiment to remain hostile.

8. Peer Financial Comparison

The peer set built by the upstream pipeline includes Coloplast (the closest pure peer in ostomy/continence/wound care), Smith & Nephew (UK med-tech overlap on advanced wound care), Solventum (formerly 3M Health Care, advanced wound care), Insulet (an Infusion Care customer/competitor), and Integra LifeSciences (small-cap wound reconstruction).

The peer gap that matters. Coloplast — the most direct comparable — generates 26% IFRS operating margin versus Convatec's 13%, ~10% ROIC versus 7.6%, and trades at 16.6x EV/EBITDA versus Convatec's 14.5x. The Coloplast-Convatec multiple gap (~2 turns) is much smaller than the operating-margin gap (~13 percentage points), which is the bull case: if Convatec executes to 24-26% adjusted operating margin by 2027, the company gets paid like Coloplast on a much larger profit base. Smith & Nephew is closer to Convatec on margins and trades at 12.2x EV/EBITDA — a useful alternative anchor implying the stock is roughly fairly priced today against the closest IFRS-margin peer. Insulet trades on growth (30% YoY revenue) at a price most med-tech investors will not pay; Solventum trades cheap because of separation/standalone risk.

9. What to Watch in the Financials

What the financials confirm. Revenue is growing again. Gross margin is stable at peer-level 56%. Cash conversion is improving and was 13.7% in FY25 — strongest in the company's listed history. Buybacks have arrived. Investment grade is held. The FISBE / Accelerate strategy is producing measurable financial outcomes.

What the financials contradict. The IFRS P&L still does not show the margin profile management is selling. ROIC remains below pure-play peer Coloplast and likely below cost of capital. Cash on the balance sheet is thin at $68M, leaving zero buffer. The FY25 H2 IFRS operating margin compression to 10.9% needs to reverse in FY26 H1 once tariff phasing normalises.

The first financial metric to watch is the FY26 adjusted operating margin print at the August half-year update. If management delivers ≥23% with H1 carrying the full tariff load — as guided — the IFRS-vs-adjusted gap thesis is validated and the ~6% FCF yield plus multiple convergence becomes the central bull case. If H1 adjusted operating margin slips to the low 22s with no clear path back, the discount to Coloplast widens and the buyback/dividend cadence will be questioned given the $68M cash position.